Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Merck has officially opened a new €300 million bioprocessing production center in Daejeon, South Korea, marking its largest Life Science investment in the Asia-Pacific region.
Revolution Medicines (RVMD) has surged over 9x in three years following FDA approval of its cancer drug Rasonque for pancreatic cancer treatment. While the stock has delivered impressive returns, analysts suggest it's unlikely to reach the $1.6 trillion market cap needed to turn a $25,000 investment into $1 million. However, with additional pipeline candidates and analyst support, the company could still generate market-beating returns for long-term investors.
Moderna stock has surged over 100% this year, driven by positive results from its personalized cancer vaccine candidate in combination with Merck's Keytruda. The company is scheduled to report Q3 earnings on Nov. 6, with investors focused on oncology progress and cancer vaccine development. While recent data leak caused a stock dip, the author expects the next major catalyst to come from fresh cancer vaccine data rather than the earnings report itself.